Shots:

• The P-III UNIFI study involves assessing the safety & efficacy of Stelara (90mg- q8w/q12w) as induction and maintenance therapy vs PBO in 588 patients with UC with inadequate response & were unable to tolerate conventional therapies
• Results: in IIT population- 55.2% were in symptomatic remission & 96.4% of the patients in symptomatic remission were corticosteroid-free @3yrs.- no new safety signals were identified. In LTE study- 91.4% receiving corticosteroids at maintenance baseline were no longer receiving corticosteroids @152wks.
• Stelara is a fully human mAb & is the first biologic treatment to selectively inhibit the IL-12 and IL-23 pathways

  Ref: J&J | Image: Janssen